Threshold And Molecular Templates Merge To Test The Power Of Two
Although a vehicle for Molecular Templates to take its Engineered Toxin Bodies oncology platform public, the combined company also will seek a pathway to approval for Threshold's evofosfamide for pancreatic cancer in Japan.
You may also be interested in...
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Threshold Pharmaceuticals saw its stock lose more than 80% of its value following disappointing data from two Phase III trials of its anticancer evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. Its partner, Germany's Merck, said it would not be filing for approval of the product.
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.